bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW),a biotechnology company advancing noninvasive diagnostics for lung cancer and other lung diseases, today announced continued sales growth of its ...
Pulmonary function tests are a group of noninvasive breathing tests that measure how much air your lungs can hold, how quickly you can move air in and out and how efficiently your lungs transfer ...
SAN ANTONIO--(BUSINESS WIRE)-- bioAffinity Technologies, Inc. (BIAF) (Nasdaq: BIAF; BIAFW), a biotechnology company advancing noninvasive diagnostics for lung cancer and other lung diseases, today ...
"The increase in CyPath Lung test volume demonstrates that physicians are increasingly recognizing the clinical value of CyPath Lung in detecting lung cancer at its earliest and most treatable stages, ...
Diagnosing lung diseases is easier than it used to be with a new state-of-the-art pulmonary function machine recently installed at St. Luke's Hospital. A Vmax Series product from Sensor Medics is a ...
SAN ANTONIO, November 05, 2025--(BUSINESS WIRE)--bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company advancing noninvasive diagnostics for lung cancer and other lung diseases ...
October test volume 111% more than 2025 year-to-date monthly average SAN ANTONIO--(BUSINESS WIRE)-- bioAffinity Technologies, Inc. (BIAF) (Nasdaq: BIAF; BIAFW), a biotechnology company advancing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback